These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37437352)

  • 1. A dual nociceptin and mu opioid receptor agonist exhibited robust antinociceptive effect with decreased side effects.
    Hsu YT; Chen SR; Chang YC; Chang HF; Yeh TK; Chuang JY; Loh HH; Hsieh HP; Ueng SH; Yeh SH
    Eur J Med Chem; 2023 Oct; 258():115608. PubMed ID: 37437352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
    Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
    Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nociceptin Receptor-Related Agonists as Safe and Non-addictive Analgesics.
    Ding H; Kiguchi N; Dobbins M; Romero-Sandoval EA; Kishioka S; Ko MC
    Drugs; 2023 Jun; 83(9):771-793. PubMed ID: 37209211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
    J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
    Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
    J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
    Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
    J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of mu-opioid agonist efficacy on antinociceptive interactions between mu agonists and the nociceptin opioid peptide agonist Ro 64-6198 in rhesus monkeys.
    Cornelissen JC; Steele FF; Tenney RD; Obeng S; Rice KC; Zhang Y; Banks ML
    Eur J Pharmacol; 2019 Feb; 844():175-182. PubMed ID: 30552903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
    Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
    Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
    Cremeans CM; Gruley E; Kyle DJ; Ko MC
    J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzo[b]thiophene-2-carboxamides as novel opioid receptor agonists with potent analgesic effect and reduced constipation.
    Kuppusamy R; Hsu YT; Ke YY; Chang PW; Chang YC; Chang HF; Wang PC; Lin YH; Huang YC; Yeh TK; Chuang JY; Loh HH; Shih C; Chen CT; Yeh SH; Ueng SH
    Eur J Med Chem; 2022 Dec; 243():114728. PubMed ID: 36084534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
    Kiguchi N; Kishioka S; Ko MC
    Nihon Yakurigaku Zasshi; 2021; 156(3):139-144. PubMed ID: 33952840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys.
    Ko MC; Woods JH; Fantegrossi WE; Galuska CM; Wichmann J; Prinssen EP
    Neuropsychopharmacology; 2009 Aug; 34(9):2088-96. PubMed ID: 19279568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
    Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
    Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
    Linz K; Schröder W; Frosch S; Christoph T
    Anesthesiology; 2017 Apr; 126(4):708-715. PubMed ID: 28291086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability.
    Lin AP; Ko MC
    ACS Chem Neurosci; 2013 Feb; 4(2):214-24. PubMed ID: 23421672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats.
    Micheli L; Di Cesare Mannelli L; Guerrini R; Trapella C; Zanardelli M; Ciccocioppo R; Rizzi A; Ghelardini C; Calò G
    Eur J Pharmacol; 2015 May; 754():73-81. PubMed ID: 25704616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction between DAMGO-NH
    Li N; Xiao J; Niu J; Zhang M; Shi Y; Yu B; Zhang Q; Chen D; Zhang N; Fang Q
    Peptides; 2023 Mar; 161():170943. PubMed ID: 36621672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effects.
    Gerak LR; Maguire DR; Cami-Kobeci G; Olson KM; Traynor JR; Husbands SM; France CP; Acevedo L; Belli B; Flynn P
    Behav Pharmacol; 2022 Sep; 33(6):377-394. PubMed ID: 35947066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.